收费全文 | 1737篇 |
免费 | 122篇 |
国内免费 | 15篇 |
耳鼻咽喉 | 3篇 |
儿科学 | 64篇 |
妇产科学 | 29篇 |
基础医学 | 213篇 |
口腔科学 | 31篇 |
临床医学 | 217篇 |
内科学 | 360篇 |
皮肤病学 | 14篇 |
神经病学 | 155篇 |
特种医学 | 96篇 |
外科学 | 152篇 |
综合类 | 50篇 |
一般理论 | 2篇 |
预防医学 | 208篇 |
眼科学 | 58篇 |
药学 | 93篇 |
肿瘤学 | 129篇 |
2023年 | 10篇 |
2022年 | 10篇 |
2021年 | 22篇 |
2020年 | 16篇 |
2019年 | 26篇 |
2018年 | 38篇 |
2017年 | 29篇 |
2016年 | 30篇 |
2015年 | 31篇 |
2014年 | 48篇 |
2013年 | 74篇 |
2012年 | 84篇 |
2011年 | 78篇 |
2010年 | 55篇 |
2009年 | 52篇 |
2008年 | 51篇 |
2007年 | 72篇 |
2006年 | 61篇 |
2005年 | 64篇 |
2004年 | 90篇 |
2003年 | 92篇 |
2002年 | 70篇 |
2001年 | 77篇 |
2000年 | 65篇 |
1999年 | 58篇 |
1998年 | 41篇 |
1997年 | 29篇 |
1996年 | 31篇 |
1995年 | 23篇 |
1994年 | 23篇 |
1993年 | 23篇 |
1992年 | 31篇 |
1991年 | 37篇 |
1990年 | 36篇 |
1989年 | 52篇 |
1988年 | 26篇 |
1987年 | 20篇 |
1986年 | 25篇 |
1985年 | 20篇 |
1984年 | 12篇 |
1983年 | 13篇 |
1981年 | 9篇 |
1980年 | 9篇 |
1976年 | 8篇 |
1975年 | 6篇 |
1973年 | 8篇 |
1972年 | 7篇 |
1971年 | 6篇 |
1968年 | 6篇 |
1967年 | 7篇 |
Labetalol administered in a small to moderate dose (first month 400 mg/day, second month average 585 mg/day) was effective in lowering blood pressure (BP) (-21/-18 mmHg, recumbent) in 11 of 13 mild essential hypertensives over an eight-week period, despite a significant (+294 ml) increase in plasma volume. The effect of propranolol (first month 160 mglday, second month average 234 mg/day) was significantly less on both blood pressure (-9/-9 mmHg) and plasma volume (+98 ml), although the pre-propranolol BP was lower and the final BP achieved on the two medications was comparable (labetalol 147/89 mmHg, propranolol 145/89
Six patients who continued labetalol for periods of up to 14 months had persistent plasma volume expansion. Three of these, taking a higher dose of labetalol, developed resistance to the drug's antihypertensive effect. Addition of a diuretic restored antihypertensive efficacy and led to a fall in plasma volume. No such plasma volume expansion was seen in six patients who were followed on long term propranolol therapy
Some plasma volume expansion with the combined alpha- beta-adrenoceptor blocker labetalol may be appropriate to its vasodilator action. Provided this effect is not excessive, it appears not to lead to resistance to its antihypertensive action. Small to moderate doses of labetalol would, therefore, seem effective without concomitant diuretic. Such sole use of labetalol could help minimise orthostatic symptoms which can be a major side effect of combination therapy 相似文献
OBJECTIVE
Limited information exists about the influence of urologic complications on health-related quality of life (HRQOL) in patients with type 1 diabetes.RESEARCH DESIGN AND METHODS
We studied 664 men and 580 women from the Diabetes Control and Complications Trial/Epidemiology of Interventions and Complications Study: mean ages were 51.6 ± 6.6 and 50.6 ± 7.2 years and duration of diabetes was 29.5 ± 4.8 and 29.8 ± 5.1 years, respectively. We assessed associations of sexual dysfunction, lower urinary tract symptoms (LUTS), and, in women, urinary incontinence (UI) with general quality of life (SF-36), perceived value of health (EuroQol-5), diabetes-related quality of life (Diabetes Quality of Life Scale [DQOL]), and psychiatric symptoms (Symptom Checklist 90-R).RESULTS
In both men and women, urologic complications adversely affected HRQOL and psychiatric symptoms, even after accounting for history of depression leading to treatment. Multivariable analyses accounting for the presence of diabetic retinopathy, neuropathy, and nephropathy also revealed substantial independent effects. In men, for example, the odds (95% CI) of a low DQOL score (≤25th percentile) were 3.01 (1.90–4.75) times greater with erectile dysfunction and 2.65 (1.68–4.18) times greater with LUTS and in women, 2.04 (1.25–3.35) times greater with sexual dysfunction and 2.71 (1.72–4.27) times greater with UI/LUTS combined compared with men and women without such complications. Similar effects were observed for the other measures.CONCLUSIONS
Sexual dysfunction and urinary complications with type 1 diabetes are associated with decreased quality of life and perceived value of health and with higher levels of psychiatric symptoms, even after accounting for other diabetes complications and depression treatment. 相似文献- Key points
Take time to invest in meaningful relationships with those who are detained; asking about the individual’s life experience and their perception of its relationship to their current presenting difficulties.
Identify the service user’s values -what’s important to them, and what gives meaning to their life – and discuss this in relation to what their worries, concerns or wishes may be for treatment.
Discuss previous experiences of involuntary admission- this can support all parties involved to consider the impact of detention upon the individual, and services.
Use problem-free discussions to normalise and help de-stigmatise mental health difficulties and support rapport building.
Provide practical support, such as food, drink and routinely allow those who are detained to gather personal belongings such as a change of clothes or a book.
Ensure advocacy services are always available and accessible for those who are detained under S136.
Where possible, avoid the use of restrictive or stigmatising practices in front of the public where possible (e.g. use of handcuffs, police vehicles as transport) to minimise risk of increasing mental health stigma.